T-cells play an important role controlling immunity against pathogens and therefore influence the outcome of human diseases. Although most T-lymphocytes co-express either CD4 or CD8, a smaller T-cell subset found the in the human peripheral blood that expresses the αβ or γδ T-cell-receptor (TCR) lacks the CD4 and CD8 co-receptors. These double negative (DN) T-cells have been shown to display important immunological functions in human diseases. To better understand the role of DN T-cells in human Mycobacterium tuberculosis, we have characterized their frequency, activation and cytokine profile in a well-defined group of tuberculosis patients, categorized as severe and non-severe based on their clinical status. Our data showed that whereas high frequency of αβ DN T-cells observed in M. tuberculosis-infected patients are associated with disease severity, decreased proportion of γδ DN T-cells are found in patients with severe tuberculosis. Together with activation of CD4+ and CD8+ T-cells, higher frequencies of both αβ and γδ DN T-cells from tuberculosis patients also express the chronic activation marker HLA-DR. However, the expression of CD69, an early activation marker, is selectively observed in DN T-cells. Interestingly, while αβ and γδ DN T-cells from patients with non-severe tuberculosis display a pro-inflammatory cytokine profile, characterized by enhanced IFN-γ, the γδ DN T-cells from patients with severe disease express a modulatory profile exemplified by enhanced interleukin-10 production. Overall, our findings suggest that αβ and γδ DN T-cell present disparate immunoregulatory potentials and seems to contribute to the development/maintenance of distinct clinical aspects of TB, as part of the complex immunological network triggered by the TB infection.
References
[1]
Fischer K, Voelkl S, Heymann J, Przybylski GK, Mondal K, et al. (2005) Isolation and characterization of human antigen-specific TCR alpha beta+ CD4(-)CD8- double-negative regulatory T cells. Blood 105: 2828–2835.
[2]
Liu MF, Yang CY, Chao SC, Li JS, Weng TH, et al. (1999) Distribution of double-negative (CD4- CD8-, DN) T subsets in blood and synovial fluid from patients with rheumatoid arthritis. Clin Rheumatol 18: 227–231.
[3]
Sieling PA, Porcelli SA, Duong BT, Spada F, Bloom BR, et al. (2000) Human double-negative T cells in systemic lupus erythematosus provide help for IgG and are restricted by CD1c. J Immunol 165: 5338–5344.
[4]
Thomson CW, Lee BP, Zhang L (2006) Double-negative regulatory T cells: non-conventional regulators. Immunol Res 35: 163–178.
[5]
Liu MF, Li JS, Weng TH, Lei HY (1998) Double-negative (CD4-CD8-) TCRalphabeta+ cells in patients with systemic lupus erythematosus. Scand J Rheumatol 27: 130–134.
[6]
Villani FN, Rocha MO, Nunes Mdo C, Antonelli LR, Magalhaes LM, et al. (2010) Trypanosoma cruzi-induced activation of functionally distinct alphabeta and gammadelta CD4- CD8- T cells in individuals with polar forms of Chagas' disease. Infect Immun 78: 4421–4430.
[7]
Antonelli LR, Dutra WO, Oliveira RR, Torres KC, Guimaraes LH, et al. (2006) Disparate immunoregulatory potentials for double-negative (CD4- CD8-) alpha beta and gamma delta T cells from human patients with cutaneous leishmaniasis. Infect Immun 74: 6317–6323.
[8]
Derrick SC, Evering TH, Sambandamurthy VK, Jalapathy KV, Hsu T, et al. (2007) Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine. Immunology 120: 192–206.
[9]
Thomssen H, Ivanyi J, Espitia C, Arya A, Londei M (1995) Human CD4-CD8- alpha beta + T-cell receptor T cells recognize different mycobacteria strains in the context of CD1b. Immunology 85: 33–40.
[10]
Janis EM, Kaufmann SH, Schwartz RH, Pardoll DM (1989) Activation of gamma delta T cells in the primary immune response to Mycobacterium tuberculosis. Science 244: 713–716.
[11]
Casetti R, Martino A (2008) The plasticity of gamma delta T cells: innate immunity, antigen presentation and new immunotherapy. Cell Mol Immunol 5: 161–170.
[12]
Gioia C, Agrati C, Goletti D, Vincenti D, Carrara S, et al. (2003) Different cytokine production and effector/memory dynamics of alpha beta+ or gamma delta+ T-cell subsets in the peripheral blood of patients with active pulmonary tuberculosis. Int J Immunopathol Pharmacol 16: 247–252.
[13]
Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19: 93–129.
[14]
Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, et al. (1993) Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150: 353–360.
[15]
Gerosa F, Paganin C, Peritt D, Paiola F, Scupoli MT, et al. (1996) Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med 183: 2559–2569.
[16]
Feng CG, Kaviratne M, Rothfuchs AG, Cheever A, Hieny S, et al. (2006) NK cell-derived IFN-gamma differentially regulates innate resistance and neutrophil response in T cell-deficient hosts infected with Mycobacterium tuberculosis. J Immunol 177: 7086–7093.
[17]
Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S (1999) The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest 116: 726–731.
[18]
Lazzarini LC, Spindola SM, Bang H, Gibson AL, Weisenberg S, et al. (2008) RDRio Mycobacterium tuberculosis infection is associated with a higher frequency of cavitary pulmonary disease. J Clin Microbiol 46: 2175–2183.
[19]
Dellabona P, Casorati G, Friedli B, Angman L, Sallusto F, et al. (1993) In vivo persistence of expanded clones specific for bacterial antigens within the human T cell receptor alpha/beta CD4-8- subset. J Exp Med 177: 1763–1771.
[20]
Porcelli S, Morita CT, Brenner MB (1992) CD1b restricts the response of human CD4-8- T lymphocytes to a microbial antigen. Nature 360: 593–597.
[21]
Barnes PF, Grisso CL, Abrams JS, Band H, Rea TH, et al. (1992) Gamma delta T lymphocytes in human tuberculosis. J Infect Dis 165: 506–512.
[22]
Stenger S, Mazzaccaro RJ, Uyemura K, Cho S, Barnes PF, et al. (1997) Differential effects of cytolytic T cell subsets on intracellular infection. Science 276: 1684–1687.
[23]
Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A (2011) Immunological biomarkers of tuberculosis. Nat Rev Immunol 11: 343–354.
[24]
Montoya CJ, Catano JC, Ramirez Z, Rugeles MT, Wilson SB, et al. (2008) Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol 127: 1–6.
[25]
Ottenhoff TH, Verreck FA, Hoeve MA, van de Vosse E (2005) Control of human host immunity to mycobacteria. Tuberculosis (Edinb) 85: 53–64.
[26]
Lawn SD, Myer L, Edwards D, Bekker LG, Wood R (2009) Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 23: 1717–1725.
[27]
Streitz M, Fuhrmann S, Powell F, Quassem A, Nomura L, et al. (2011) Tuberculin-specific T cells are reduced in active pulmonary tuberculosis compared to LTBI or status post BCG vaccination. J Infect Dis 203: 378–382.
[28]
Almeida AS, Lago PM, Boechat N, Huard RC, Lazzarini LC, et al. (2009) Tuberculosis is associated with a down-modulatory lung immune response that impairs Th1-type immunity. J Immunol 183: 718–731.
[29]
Bruns H, Meinken C, Schauenberg P, Harter G, Kern P, et al. (2009) Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 119: 1167–1177.
[30]
Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, et al. (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561–572.
[31]
Adams LB, Mason CM, Kolls JK, Scollard D, Krahenbuhl JL, et al. (1995) Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. J Infect Dis 171: 400–405.
[32]
Botha T, Ryffel B (2003) Reactivation of latent tuberculosis infection in TNF-deficient mice. J Immunol 171: 3110–3118.
[33]
Byrd TF (1997) Tumor necrosis factor alpha (TNFalpha) promotes growth of virulent Mycobacterium tuberculosis in human monocytes iron-mediated growth suppression is correlated with decreased release of TNFalpha from iron-treated infected monocytes. J Clin Invest 99: 2518–2529.
[34]
Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098–1104.
[35]
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48: 2122–2127.
[36]
Sai Priya VH, Latha GS, Hasnain SE, Murthy KJ, Valluri VL (2010) Enhanced T cell responsiveness to Mycobacterium bovis BCG r32-kDa Ag correlates with successful anti-tuberculosis treatment in humans. Cytokine 52: 190–193.
[37]
O'Garra A, Barrat FJ, Castro AG, Vicari A, Hawrylowicz C (2008) Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 223: 114–131.
[38]
Jankovic D, Trinchieri G (2007) IL-10 or not IL-10: that is the question. Nat Immunol 8: 1281–1283.
[39]
Boussiotis VA, Tsai EY, Yunis EJ, Thim S, Delgado JC, et al. (2000) IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 105: 1317–1325.
[40]
Gong JH, Zhang M, Modlin RL, Linsley PS, Iyer D, et al. (1996) Interleukin-10 downregulates Mycobacterium tuberculosis-induced Th1 responses and CTLA-4 expression. Infect Immun 64: 913–918.
[41]
Redford PS, Boonstra A, Read S, Pitt J, Graham C, et al. (2010) Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol 40: 2200–2210.
[42]
Ueta C, Tsuyuguchi I, Kawasumi H, Takashima T, Toba H, et al. (1994) Increase of gamma/delta T cells in hospital workers who are in close contact with tuberculosis patients. Infect Immun 62: 5434–5441.
